Heterogeneous phenotype of human glioblastoma: In vitro study

Cell Biochemistry and Function

Volumn 32, Issue 2, 2014, Pages 164-176

  Denysenko, Tetyana ^a   Gennero, Luisa ^b   Juenemann, Carola ^a   Morra, Isabella ^a   Masperi, Paolo ^c   Ceroni, Vincenzo ^c   Pragliola, Antonella ^c   Ponzetto, Antonio ^d   Melcarne, Antonio ^a  

^a CTO HOSPITAL   (Italy)

^b Medestea Research and Production Laboratories   (Italy)

^c Laboratorio Unico di Area Vasta Romagna   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer stem cells; CD133; Glioblastoma; Glioblastoma subtypes; Hydroxyurea

Indexed keywords

BETA1 INTEGRIN; CD133 ANTIGEN; CD146 ANTIGEN; CD44V ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYUREA; NESTIN; PROTEIN P53; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; ANTINEOPLASTIC AGENT; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ADULT; AGED; ARTICLE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPING; MALE; MESENCHYME CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; TUMOR RESISTANCE; APOPTOSIS; BRAIN TUMOR; DRUG EFFECTS; DRUG RESISTANCE; GENETIC HETEROGENEITY; GENETICS; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PHYSIOLOGY;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC HETEROGENEITY; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; HYDROXYUREA; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; PEPTIDES; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 84895559684     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2988     Document Type: Article

References (45)

1. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21(21): 2683-2710.
2. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10): 755-768.
4. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15(11): 1311-33.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
6. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N Engl J Med 2005; 353: 811-822.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective isolation of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
9. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-7021.
10. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
11. Barcellos-Hoff MH, Newcomb EW, Zagzag D, Narayana A. Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol 2009; 19(3): 163-170.
12. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006; 12(3): 296-300.
13. Dirks PB. Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philos Trans R Soc Lond B Biol Sci 2008; 363: 139-152.
14. Yuan X, Curtin J, Xiong Y, et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004; 23(58): 9392-9400.
15. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-15183.
16. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67(9): 4010-4015.
17. Wang J, Sakariassen PØ, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008; 122(4): 761-768.
18. Denysenko T, Gennero L, Roos MA, et al. Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct 2010; 28(5): 343-51.
19. Lottaz C, Beier D, Meyer K, et al. Transcriptional profiles of CD133+ and CD133 glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010; 70(5): 2030-40.
20. Günther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008; 27: 2897-2909.
21. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1): 98-110.
22. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
23. Ignatova TN, Kukekov BG, Ed L, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 2002; 39: 193-206.
24. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
25. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006; 5: 67.
26. Wiltshire RN, Rasheed BK, Friedman HS, Friedman AH, Bigner SH. Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification. Neuro Oncol 2000; 2(3): 164-73.
27. Coons SW, Johnson PC, Shapiro JR. Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade human. Cancer Res 1995; 55(7): 1569-77.
28. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88(8): 808-15.
29. Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch Neurol 2008; 65(7): 877-883.
30. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006; 66(23): 11502-11513.
31. Kang MK, Kang SK. Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev 2007; 16(5): 837-47.
32. Tso CL, Shintaku P, Chen J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 2006; 4(9): 607-619.
33. Carro MS, Lim WK, Alvarez MJ, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318-325.
34. Silva WA, Jr, Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003; 21: 661-9.
35. Barry FP, Boynton RE, Haynesworth S, Murphy JM, Zaia J. The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 1999; 265: 134-9.
36. Jacobsen PF, Papadimitriou JM. Mesenchymal differentiation of cell lines obtained from human gliomas inoculated into nude mice. Cancer 1989; 63: 682-92.
37. Juillerat-Jeanneret L, Bernasconi CC, Bricod C, et al. Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. Cancer Invest 2008; 26(6): 597-609.
38. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12.
39. Gronthos S, Simmons PJ, Graves SE, Robey PG. Integrin-mediated interactions between human bone marrow stromal precursor cells and the extracellular matrix. Bone 2001; 28: 74-181.
40. Hendricks SP, Mathews CK. Allosteric regulation of vaccinia virus ribonucleotide reductase, analyzed by simultaneous monitoring of its four activities. J Biol Chem 1998; 273: 29519-29523.
41. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19: 11-19.
42. Huyghe P, Dassonneville L, Fenaux P, Bailly C. Hydroxyurea induced apoptosis in an EBV-immortalized lymphoblastoid cel line. Oncol Res 2004; 14: 235-245.
43. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1-10.
44. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005; 16(10): 1702-1708.
45. Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW. Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen. J Neurooncol 2009; 93(3): 425-30.